EC Number   |
Inhibitors |
Structure |
|---|
   3.4.21.45 | 2-mercaptoethanol |
10 mM, strong |
   |
| 3.4.21.45 | 4-(2-aminoethyl)benzenesulfonyl fluoride |
0.25 mM, inhibits SP domain form and fI |
|
| 3.4.21.45 | amyloid beta |
binds to complement factor I which inhibits the ability of factor I to cleave C3b to inactivated C3b. Addition of factor I restores inactivated C3b production in amyloid beta-treated RPE cells. Preincubation of factor I with amyloid beta in the presence of factor H abolishes the ability of factor I to cleave FGR-7-amino-4-methylcoumarin |
|
| 3.4.21.45 | amyloid beta |
production of inactivated C3b is significantly decreased when C3b and factor H are incubated with eyes from neprilysin gene-disrupted mice, which leads to an increased deposition of amyloid beta, compared with when C3b and factor H are incubated with eyes from wild-type mice |
|
| 3.4.21.45 | antipain |
0.1 mM, 80% inhibition of amidolytic activity |
|
| 3.4.21.45 | antipain |
0.1 mM, inhibits SP domain form and fI |
|
| 3.4.21.45 | Aprotinin |
0.0005 mM, 23% inhibition of proteolytic activity. 0.0005 mM, 37% inhibition of amidolytic activity |
|
| 3.4.21.45 | Aprotinin |
0.005 mM, inhibits SP domain form and fI |
|
| 3.4.21.45 | benzamidine |
20 mM, 82% inhibition of amidolytic activity |
|
| 3.4.21.45 | benzenesulfonyl fluorides |
inhibits amidolytic activity |
|
